Top

Published in:

01-02-2006 | Nuclear Medicine

Combined SPECT/CT imaging using ¹²³I-IMT in the detection of recurrent or persistent head and neck cancer

Authors: Michail Plotkin, Reinhard Wurm, Julia Eisenacher, Katarzyna Szerewicz, Roger Michel, Lorenz Schlenger, Maciej Pech, Timm Denecke, David Kuczer, Annet Bischoff, Roland Felix, Holger Amthauer

Published in: European Radiology | Issue 2/2006

Abstract

The aim of the study was to assess the clinical value of combined SPECT/CT imaging using L-3-[123I]iodine-α-methyl tyrosine (IMT) for the differential diagnosis of recurrences in patients pre-treated for head and neck cancer. Thirty-four consecutive patients with biopsy-proven carcinomas, who had previously been treated by surgery and/or radio/chemotherapy, were examined at our clinic by IMT-SPECT using a dual-head system with integrated low-dose CT. SPECT results were correlated with histopathology, clinical and CT/MRI follow-up data. In the follow-up after SPECT examination, the final diagnosis of recurrent tumour was established in 26 patients; the remaining eight patients were recurrence-free (follow-up >6 months). IMT-SPECT/CT correctly detected recurrent disease and/or neck lymph node metastases in 22 patients. In addition, distant metastases were displayed in two patients. The study was false-negative in four patients (sensitivity 85%). True-negative results were registered in seven patients, and false-positive in one patient. Image fusion with coregistered low-dose CT facilitates the localisation and interpretation of IMT-SPECT findings. IMT-SPECT using integrated low-dose CT is a promising non-invasive imaging tool for the detection of head and neck cancer recurrences and their differentiation from treatment-induced changes.

Myers E, Leffall L (1991) Head and neck oncology: diagnosis, treatment and rehabilitation. Little Brown, Boston

Bronstein AD, Nyberg DA, Schrarzt AN, Shuman WP, Griffin BR (1989) Soft-tissue changes after head and neck radiation: CT findings. Am J Neuroradiol 10:171–175

Som PM (1992) Detection of metastasis in cervical lymph nodes: CT and MR citeria and differential diagnosis. Am J Roentgenol 158:961–969

Chisin R (1999) Nuclear medicine in head and neck oncology: reality and perspectives. J Nucl Med 40:91–95

Davis JP, Maisey NM, Chevreton EB (1998) Positron emission tomography: a useful imaging technique for otolaryngology, head and neck surgery? J Laryngol Otol 112:125–127PubMed

Baum U, Anders K, Steinbichler G, Lell M, Greess H, Riedel T, Kachelriess M, Kalender WA, Bautz WA (2004) Improvement of image quality of multislice spiral CT scans of the head and neck region using a raw data-based multidimensional adaptive filtering (MAF) technique. Eur Radiol 14:1873–1881CrossRefPubMed

Lapela M, Grenman R, Kurki T, Joensuu H, Leskinen S, Lindholm P, Haaparanta M, Ruotsalainen U, Minn H (1995) Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 197:205–211PubMed

Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, Chalian AA, Alavi A, Rosenthal DI (1999) Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 109:970–975PubMed

Fischbein NJ, AAssar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, Dillon WP, Hawkins RA (1998) Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 19:1189–1196PubMed

10.

Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC (1998) Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 16:3550–3555PubMed

11.

Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199–4208PubMed

12.

Yamada S, Kubota K, Kubota R, Ido T, Tamashashi N (1995) High accumulation of fluorine-fluorodeoxyglucose in terpentine-induced inflammatory tissue. J Nucl Med 36:1301–1306PubMed

13.

Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H (1997) Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of flouorodeoxyglucose, L-methionine and thymidine. J Nucl Med 38:280–287PubMed

14.

Hautzel H, Müller-Gärtner HW (1997) Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 38:1384–1386PubMed

15.

Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H (1992) Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 33:691–695PubMed

16.

Lindholm P, Leskinen-Kallio S, Grenman R, Lehikoinen P, Nagren K, Teras M, Ruotsalainen U, Joensuu H (1995) Evaluation of response to therapy in head and neck cancer by positron emission tomography and [11C]methionine. Int J Radiat Oncol Biol Phys 32:787–794PubMed

17.

Nuutinen J, Jyrkkio S, Lehikoinen P, Lindholm P, Minn H (1999) Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography. Radiother Oncol 52:225–232PubMed

18.

Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A, Sobrio F, Moreau S (2003) Early response to chemotherapy in hypophyryngeal cancer: assessment with (11)C-methionine PET. Correlation with morphologic response, and clinical outcome. J Nucl Med 44:526–532PubMed

19.

Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE (1990) SPECT studies of brain tumors with L-3-[123]iodo-a-methyltyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med 31:281–286PubMed

20.

Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW (1997) 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 38:517–522PubMed

21.

Langen K-J, Pauleit D, Coenen HH (2002) 3-(123I)-Iodo-a-methyl-L-tyrosne: uptake mechanisms and clinical applications. Nucl Med Biol 29:625–631PubMed

22.

Dierickx LO, Everaert H, Deron P, Voordeckers M, Lahoutte T, Bossuyt A (2003) Evaluation of the response to therapy of head and neck squamous cell carcinoma by using 3-[123I]iodo-L-alpha-methyl tyrosine and single photon emission tomography. Nucl Med Commun 24:633–641PubMed

23.

Flamen P, Bernheim N, Deron P, Caveliers V, Chavatte K, Franken PR, Bossuyt A (1998) Iodine-123 alpha-methyl-l-tyrosine single-photon emission tomography for the visualization of head and neck squamous cell carcinomas. Eur J Nucl Med 25:177–181PubMed

24.

Dierickx LO, Lahoutte T, Deron P, Caveliers V, Vanhove C, Everaert H, Bossuyt A (2001) Diagnosis of recurrent head and neck squamous cell carcinoma with 3-[123I]iodo-L-alpha-methyltyrosine SPET. Eur J Nucl Med 28:282–287

25.

Tomura N, Watanabe O, Omachi K, Sakuma I, Takahashi S, Otani T, Kidani H, Watarai J (2004) Image fusion of thallium-201 SPECT and MR imaging for the assessment of recurrent head and neck tumors following flap reconstructive surgery. Eur Radiol 14:1249–1254

26.

Krummreich C, Holsbach M, Stöcklin G (1994) Direkt electrophilic radioiodination of tyrosine analogues: their in-vivo stability and brain uptake in mice. Appl Radiat Isotopes 45:929–935CrossRef

27.

Biersack HJ, Coenen HH, Stocklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O (1989) Imaging of brain tumors with L-3-[¹²³I]iodo-α-methyl tyrosine and SPECT. J Nucl Med 30:110–112PubMed

28.

Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, Feiden W, Kirsch CM (2002) Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis or recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 15:396–404CrossRef

29.

Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O (1998) Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 39:23–27PubMed

30.

Matheja P, Weckesser M, Rickert C, Franzius C, Palkovic S, Riemann B, Schober O (2002) I-123-lodo-alpha-methyl tyrosine SPECT in non-parenchymal brain tumours. Nuklearmediziner 41:191–196

31.

Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer R, Feußner A, Dudeck O, Wust P, Felix R, Amthauer H (2004) ¹²³I-IMT SPECT and ¹H MR-spectroscopy at 3.0 Tesla in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neuro-oncol 70:49–58CrossRef

32.

Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust R, Stockhammer F, Gutberlet M, Röttgen R, Ruf J, Felix R (2005) Value of ¹²³I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology 47:18–26PubMed

33.

Pauleit D, Floeth F, Tellmann L, Hamacher H, Hautzel H, Müller HW, Coenen HH, Langen KJ (2004) Comparison of O-(2-18F-fluoroethyl)-L-tyrosinePET and 3-123I-iodo-α-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 45:374–381PubMed

34.

Jager PL, Franssen EJ, Kool W, Szabo BG, Hoekstra HJ, Groen HJ, de Vries EG, van Imhoff GW, Vaalburg W, Piers DA (1998) Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors. J Nucl Med 39:1736–1743PubMed

35.

Jager PL, Groen HJ, van der Leest A, van Putten JW, Pieterman RM, de Vries EG, Piers DA (2001) L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations. J Nucl Med 42:579–585PubMed

36.

Willkomm P, Bangard M, Guhlke S, Sartor J, Bender H, Gallkowski U, Reichmann K, Biersack HJ (2002) Comparison of [18F]FDG-PET and L-3[123I]-iodo-alpha-methyl tyrosine (I-123 IMT)-SPECT in primary lung cancer. Ann Nucl Med 16:503–506PubMed

37.

Jager PL, Plaat BE, de Vries EG, Molenaar WM, Vaalburg W, Piers DA, Hoekstra HJ (2000) Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res 6:2252–2259PubMed

38.

Jager PL, Meijer WG, Kema IP, Willemse PH, Piers DA, de Vries EG (2000) L-3-[123I]Iodo-alpha-methyltyrosine scintigraphy in carcinoid tumors: correlation with biochemical activity and comparison with [111In-DTPA-D-Phe1]-octreotide imaging. J Nucl Med 41:1793–1800PubMed

39.

Steinert H, Boni R, Huch-Boni RA, Capaul R, von Schulthess GK, Westera G (1997) [123I]-alpha-methyltyrosine scintigraphy in malignant melanoma. Nuklearmediziner 36:36–41

40.

Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U (2002) Pretreatment evaluation of carcinomas of the hypopharynx and larynx with ¹⁸F-fluorodeoxyglucose, ¹²³I-alpha-methyl-L-tyrosine and ^99mTc-hexakis-2-methoxyisobutylisonitrile. Eur J Nucl Med Mol Imaging 29:324–330PubMed

41.

Ruf J, Lehmkuhl L, Bertram H, Sandrock D, Amthauer H, Humplik B, Munz DL, Felix R (2004) Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 25:1177–1182PubMed

42.

Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD, Bares R (2003) Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 30:835–843PubMed

43.

Kaczirek K, Prager G, Kienast O, Dobrozemsky G, Dudczak R, Niederle B, Kurtaran A (2003) Combined transmission and (99m)Tc-sestamibi emission tomography for localization of mediastinal parathyroid glands. Nuklearmediziner 42:220–223

44.

Ozer S, Dobrozemsky G, Kienast O, Beheshti M, Becherer A, Niederle B, Kainberger F, Dudczak R, Kurtaran A (2004) Value of combined XCT/SPECT technology for avoiding false positive planar (123)I-MIBG scintigraphy. Nuklearmediziner 43:164–170

45.

Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, Lacau-Saint-Guily J, Laugier A, Schlienger M (1994) Synchronous and metachronous head and neck carcinomas. Cancer 74:1933–1938PubMed

Title: Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer
Authors: Michail Plotkin
Reinhard Wurm
Julia Eisenacher
Katarzyna Szerewicz
Roger Michel
Lorenz Schlenger
Maciej Pech
Timm Denecke
David Kuczer
Annet Bischoff
Roland Felix
Holger Amthauer
Publication date: 01-02-2006
Publisher: Springer-Verlag
Published in: European Radiology / Issue 2/2006
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-005-2832-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combined SPECT/CT imaging using ¹²³I-IMT in the detection of recurrent or persistent head and neck cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2006

Left ventricular function studied with MDCT

MR-guided biopsies of lesions in the retroperitoneal space: technique and results

Comparison of radiology residency programs in ten countries

Atraumatic avulsion of the lesser trochanter as an indicator of tumour infiltration

Primitive mesenteric gastrointestinal stromal tumor with autonomic nerve/ganglionic differentiation presenting as a huge mass with small synchronous nodules

Automatic determination of minimal cardiac motion phases for computed tomography imaging: initial experience